Display options
Cite
Arnaldi G, Cardinaletti M, Boscaro M. Advances in medical treatment of Cushing's disease. Expert Rev Endocrinol Metab. 2007;2(6):735-743doi: 10.1586/17446651.2.6.735.
Arnaldi, G., Cardinaletti, M., & Boscaro, M. (2007). Advances in medical treatment of Cushing's disease. Expert review of endocrinology & metabolism, 2(6), 735-743. https://doi.org/10.1586/17446651.2.6.735
Arnaldi, Giorgio, et al. "Advances in medical treatment of Cushing's disease." Expert review of endocrinology & metabolism vol. 2,6 (2007): 735-743. doi: https://doi.org/10.1586/17446651.2.6.735
Arnaldi G, Cardinaletti M, Boscaro M. Advances in medical treatment of Cushing's disease. Expert Rev Endocrinol Metab. 2007 Nov;2(6):735-743. doi: 10.1586/17446651.2.6.735. PMID: 30290469.
Copy Download .nbib Format: NLM
Share it on

Expert Rev Endocrinol Metab. 2007 Nov;2(6):735-743. doi: 10.1586/17446651.2.6.735.

Advances in medical treatment of Cushing's disease.

Expert review of endocrinology & metabolism

Giorgio Arnaldi, Marina Cardinaletti, Marco Boscaro

Affiliations

  1. a Azienda Ospedaliero-Universitaria, Clinica di Endocrinologia, Ospedali Riuniti di Ancona, 60100 Ancona, Italy. [email protected]; [email protected].
  2. b Polytechnic University of Marche Region, Division of Endocrinology, Department of Internal Medicine, Ancona, Italy. [email protected].
  3. c Polytechnic University of Marche Region, Division of Endocrinology, Department of Internal Medicine, Ancona, Italy. [email protected].

PMID: 30290469 DOI: 10.1586/17446651.2.6.735

Abstract

It is well known that transphenoidal surgery is the first line of treatment for Cushing's disease (CD). In case of recurrence, pituitary irradiation or adrenalectomy are usually performed; however, the morbidity due to these procedures is not negligible. For this reason, there is still a strong need for medical therapy, although there are only a few controlled data on this field. A variety of compounds are invaluable complementary tools in the management of this serious condition for which no treatment has yet been proven fully satisfactory. Pharmacological treatment could be employed by using neuromodulatory drugs (i.e., serotonin antagonists, dopamine, and GABA agonists) active only in a few cases of hypothalamic-pituitary-dependent CD. New approaches at the pituitary tumor level involve the potential use of other compounds (e.g., PPAR-γ agonists and retinoic acid). Exciting news in treating CD includes the recent availability of new multiligand somatostatin analogues. This review focuses on the new potential pharmacologic approaches for the management of CD based on the recent identification of possible targets and/or pathogenetic mechanisms.

Keywords: Cushing’s disease; cabergoline; neuromodulators; pasireotide (SOM230); retinoid acid; steroidogenesis inhibitors; thiazolidinediones

Publication Types